Reviews

Mitochondrial gene heterogeneity related to MELAS syndrome: A review of literature

  • Limin WEN ,
  • Ran LI ,
  • Yanlei HAO ,
  • Qingxia KONG ,
  • Min. XIA
Expand
  • Clinical Medicine College,Jining Medical University,Jining 272067,China

Received date: 2023-11-23

  Online published: 2024-07-09

Abstract

MELAS syndrome is a genetic disease caused by mutations in mitochondrial DNA (mtDNA) or nuclear DNA. Eighty percent of the cases are caused by m.3243A>G mutation. Heteroplasmy, defined as the presence of both normal and mutant mtDNA in cells, is related with the severity of MELAS syndrome. This article reviews the research in mtDNA heterogeneity related to MELAS syndrome, aiming to provide an insight into new therapies for the syndrome.

Cite this article

Limin WEN , Ran LI , Yanlei HAO , Qingxia KONG , Min. XIA . Mitochondrial gene heterogeneity related to MELAS syndrome: A review of literature[J]. The Journal of Practical Medicine, 2024 , 40(13) : 1885 -1888 . DOI: 10.3969/j.issn.1006-5725.2024.13.021

References

1 北京医学会罕见病分会, 北京医学会神经内科分会神经肌肉病学组, 中国线粒体病协作组. 中国线粒体脑肌病伴高乳酸血症和卒中样发作的诊治专家共识[J]. 中华神经科杂志, 2020,53(3):171-178. doi:10.3760/cma.j.issn.1006-7876.2020.03.003
2 王凯莉, 陈卫刚, 丁新, 等. 线粒体转录因子A在食管鳞癌中的表达及其机制[J].实用医学杂志, 2020,36(9):1164-1171. doi:10.3969/j.issn.1006-5725.2020.09.010
3 RUSSELL O, TURNBULL D. Mitochondrial DNA disease-molecular insights and potential routes to a cure[J]. Exp Cell Res, 2014, 325(1): 38-43. doi:10.1016/j.yexcr.2014.03.012
4 SKEIE J M, NISHIMURA D Y, WANG C L, et al. Mitophagy: An Emerging Target in Ocular Pathology[J]. Invest Ophthalmol Vis Sci, 2021,62(3):22. doi:10.1167/iovs.62.3.22
5 金晶, 刘雨朦, 张栋, 等. 缺氧条件下CK1δ和PER1可调控BV2细胞的线粒体形态[J].实用医学杂志,2021,37(9):1111-1116. doi:10.3969/j.issn.1006-5725.2021.09.003
6 SUZUKI T, NAGAO A, SUZUKI T. Human mitochondrial tRNAs: biogenesis, function, structural aspects, and diseases[J]. Annu Rev Genet, 2011,45:299-329. doi:10.1146/annurev-genet-110410-132531
7 DUCHEN M R, SZABADKAI G. Roles of mitochondria in human disease[J]. Essays Biochem, 2010,47:115-137. doi:10.1042/bse0470115
8 NG Y S, BINDOFF L A, GORMAN G S, et al. Mitochondrial disease in adults: recent advances and future promise[J]. Lancet Neurol, 2021,20(7):573-584. doi:10.1016/s1474-4422(21)00098-3
9 FAN H C, LEE H F, YUE C T, et al. Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes[J]. Life (Basel), 2021, 11(11):1111. doi:10.3390/life11111111
10 MAJAMAA K, MOILANEN J S, UIMONEN S, et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population[J]. Am J Hum Genet, 1998,63(2):447-454. doi:10.1086/301959
11 GOTO Y, NONAKA I, HORAI S. A mutation in the tRNA (Leu) (UUR) gene associated w ith the MELAS subgroup of mitochondrial encephalomyopathies[J]. Nature, 1990,348(6302):651-653. doi:10.1038/348651a0
12 IKEDA T, OSAKA H, SHIMBO H, et al. Mitochondrial DNA 3243A > T mutation in a patient with MELAS syndrome[J]. Hum Genome Var, 2018, 5: 25. doi:10.1038/s41439-018-0026-6
13 DE LAAT P, KOENE S, VAN DEN HEUVEL L P, et al. Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A>G mutation[J]. J Inherit Metab Dis, 2012,35(6):1059-1069. doi:10.1007/s10545-012-9465-2
14 GRADY J P, PICKETT S J, NG Y S, et al. mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease[J]. EMBO Mol Med, 2018,10(6):e8262. doi:10.15252/emmm.201708262
15 BOGGAN R M, LIM A, TAYLOR R W, et al. Resolving complexity in mitochondrial disease: Towards precision medicine[J]. Mol Genet Metab, 2019,128(1/2):19-29. doi:10.1016/j.ymgme.2019.09.003
16 SCHOLLE L M, ZIERZ S, MAWRIN C, et al. Heteroplasmy and Copy Number in the Common m.3243A>G Mutation-A Post-Mortem Genotype-Phenotype Analysis[J]. Genes (Basel), 2020,11(2):212. doi:10.3390/genes11020212
17 LAZO S, NOREN H N, GREEN J, et al. Mitochondrial DNA in extracellular vesicles declines with age[J]. Aging Cell, 2021,20(1):e13283. doi:10.1111/acel.13283
18 CARDENAS-ROBLEDO S, SABER TEHRANI A, BLUME G, et al. Visual, Ocular Motor, and Cochleo-Vestibular Loss in Patients With Heteroplasmic, Maternally-Inherited Diabetes Mellitus and Deafness (MIDD), 3243 Transfer RNA Mutation[J]. J Neuroophthalmol, 2016,36(2):134-140. doi:10.1097/wno.0000000000000340
19 ZHANG R, WANG Y, YE K, et al. Independent impacts of aging on mitochondrial DNA quantity and quality in humans[J]. BMC Genomics, 2017,18(1):890. doi:10.1186/s12864-017-4287-0
20 WALKER M A, LAREAU C A, LUDWIG L S, et al. Purifying Selection against Pathogenic Mitochondrial DNA in Human T Cells[J]. N Engl J Med, 2020,383(16):1556-1563. doi:10.1056/nejmoa2001265
21 GRIGALIONIENE? K, BURNYT? B, AMBROZAITYT? L, et al. Wide diagnostic and genotypic spectrum in patients with suspected mitochondrial disease[J]. Orphanet J Rare Dis, 2023, 18(1): 307. doi:10.1186/s13023-023-02921-0
22 SHI Y, CHEN G, SUN D, et al. Phenotypes and genotypes of mitochondrial diseases with mtDNA variations in Chinese children: A multi-center study[J]. Mitochondrion, 2022, 62: 139-150. doi:10.1016/j.mito.2021.11.006
23 CHAKRABARTY S, GOVINDARAJ P, SANKARAN B P, et al. Contribution of nuclear and mitochondrial gene mutations in mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome[J]. J Neurol, 2021, 268(6): 2192-2207. doi:10.1007/s00415-020-10390-9
24 RONG E, WANG H, HAO S, et al. Heteroplasmy Detection of Mitochondrial DNA A3243G Mutation Using Quantitative Real-Time PCR Assay Based on TaqMan-MGB Probes[J]. Biomed Res Int, 2018,2018:1286480. doi:10.1155/2018/1286480
25 TOMITA K, INDO H P, SATO T, et al. Development of a sensitive double TaqMan Probe-based qPCR Angle-Degree method to detect mutation frequencies[J]. Mitochondrion, 2023, 70: 1-7. doi:10.1016/j.mito.2023.02.010
26 SHOOP W K, GORSUCH C L, BACMAN S R, et al. Precise and simultaneous quantification of mitochondrial DNA heteroplasmy and copy number by digital PCR[J]. J Biol Chem, 2022,298(11):102574. doi:10.1016/j.jbc.2022.102574
27 FAYSSOI A, LAFORêT P, BOUGOUIN W, et al. Prediction of long-term prognosis by heteroplasmy levels of the m.3243A>G mutation in patients with the mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome[J]. Eur J Neurol, 2017,24(2):255-261. doi:10.1111/ene.13176
28 NG Y S, LAX N Z, BLAIN A P, et al. Forecasting stroke-like episodes and outcomes in mitochondrial disease[J]. Brain, 2022,145(2):542-554. doi:10.1093/brain/awab353
29 LIEW S S, QIN X, ZHOU J, et al. Smart Design of Nanomaterials for Mitochondria-Targeted Nanotherapeutics[J]. Angew Chem Int Ed Engl, 2021,60(5):2232-2256. doi:10.1002/anie.201915826
30 KHAN S H. Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application[J]. Mol Ther Nucleic Acids, 2019,16:326-334. doi:10.1016/j.omtn.2019.02.027
31 FOLMES C D, MARTINEZ-FERNANDEZ A, PERALES-CLEMENTE E, et al. Disease-causing mitochondrial heteroplasmy segregated within induced pluripotent stem cell clones derived from a patient with MELAS[J]. Stem Cells, 2013,31(7):1298-1308. doi:10.1002/stem.1389
32 LATCHMAN K, SAPORTA M, MORAES C T. Mitochondrial dysfunction characterized in human induced pluripotent stem cell disease models in M6ELAS syndrome: A brief summary[J]. Mitochondrion, 2023, 72: 102-105. doi:10.1016/j.mito.2023.08.003
33 POVEA-CABELLO S, VILLANUEVA-PAZ M, VILLALóN-GARCíA I, et al. Modeling Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes Syndrome Using Patient-Derived Induced Neurons Generated by Direct Reprogramming[J]. Cell Reprogram, 2022, 24(5): 294-303. doi:10.1089/cell.2022.0055
34 LIN D, HUANG Y, HO C, et al. Impact of Mitochondrial A3243G Heteroplasmy on Mitochondrial Bioenergetics and Dynamics of Directly Reprogrammed MELAS Neurons[J]. Cells, 2023,12(1):15. doi:10.3390/cells12010015
Outlines

/